CD388 – Talk Bio

Actionable Insights Powered by AI

Merck to Acquire Cidara Therapeutics for $9.2 Billion

3 weeks ago talkbio0Tagged Acquisition, Antiviral Agents, Breakthrough Therapy Designation, CD388, Cidara Therapeutics, Immunostimulating conjugate (antigen), influenza prevention, Merck

Merck; Cidara Therapeutics; acquisition; $9.2 billion; CD388; influenza prevention; antiviral; drug-Fc conjugate; Breakthrough Therapy Designation; Keytruda

Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push

2 months ago talkbio0Tagged Acquisition, Antiviral Agents, Breakthrough Therapy, CD388, Cidara Therapeutics, Influenza, J&J, Merck, Phase 3, sanofi, United States Food and Drug Administration

Merck; Cidara Therapeutics; CD388; antiviral; acquisition; influenza; phase 3; FDA Breakthrough Therapy; J&J; Sanofi; Keytruda